Update on Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)

Authors
Jan Hoffmann, Arne May

Affiliation
Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Hamburg

Key words
pseudotumor cerebri, idiopathic intracranial hypertension, headache

Bibliography
DOI https://doi.org/10.1055/s-0043-113034
Neurology International Open 2017; 1: E224–E231
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 2511-1795

Correspondence
PD Dr. med. Jan Hoffmann
Department of Systems Neuroscience
University Medical Center Hamburg-Eppendorf
Martinistraße 52
20246 Hamburg
j-r.hoffmann@uke.de

ABSTRACT
Idiopathic intracranial hypertension is characterized by an increase of intracranial pressure of unknown etiology. The clinical presentation is dominated by progressive visual disturbances, which are commonly the result of a papilledema, headache and cranial nerve palsies. Clinical studies have revealed over the past years that the syndrome may also be associated with olfactory disturbances, cognitive deficits and a pulsatile tinnitus. The underlying pathomechanism is probably based on a disturbance of venous outflow, which causes a reduced absorption of cerebrospinal fluid that results in an increase of cerebrospinal fluid pressure. It remains unclear if the venous outflow disturbance results from the overweight-induced increase of intrathoracic pressure, the presence of sinus vein stenoses or both conditions. Recently hormonal factors have also been discussed, but the mechanisms behind a potential influence on intracranial pressure remain unclear.

Treatment of idiopathic intracranial hypertension relies mainly on an effective body weight reduction and medication with carboanhydrase inhibitors, which can reduce the production of cerebrospinal fluid and body weight. Results of the first randomized, placebo-controlled trial as well as a 12-month follow-up show that acetazolamide effectively reduces papilledema, visual disturbances and headache in idiopathic intracranial hypertension. In contrast, the evidence for the carboanhydrase inhibitors topiramate and furosemide still relies on open-label trials, because double-blind, placebo-controlled trials for their efficacy in idiopathic intracranial hypertension do not exist. In addition to the treatment with carboanhydrase inhibitors, increasing evidence suggests that the somatostatin analog octreotide may be effective in the treatment of idiopathic intracranial hypertension, but to date no randomized, double-blind, placebo-controlled trials exist to confirm this observation.

Introduction
In 1904 the German neurologist Max Nonne introduced the term pseudotumor cerebri (PTC) to describe the clinical syndrome of chronically elevated intracranial pressure of unknown etiology. As diagnostic options grew broader and more effective over time, however, numerous pathological conditions that can cause chronically high intracranial pressure were identified, which occasioned its classification into a primary and secondary form.

For years the term pseudotumor cerebri has been used as an umbrella term for chronic intracranial hypertension without further specifying its underlying cause. Pseudotumor cerebri has a primary form, idiopathic intracranial hypertension (IIH), and various secondary forms that can co-occur with other diseases, such as cerebral venous sinus thrombosis or hormonal changes[1, 2]. The following review is limited to the primary form of PTC.

The prevalence of IIH is 8.6 cases per 100 000 in the general population [3, 4], although the number is probably much higher considering that existing epidemiological studies are several decades old and apply different diagnostic criteria. Moreover, because the clinical presentation of IIH can be so similar to other primary headache disorders such as migraine or tension-type headache, especially their chronic forms, the disease may be underdiagnosed [5, 6]. Furthermore, most persons suffering from IIH are overweight [7, 8]; against the backdrop of increasing worldwide obesity, the
prevalence of IIH is also assumed to be growing [9]. In approximately 90% of adult cases, IIH affects women of reproductive age [10], although the relationship to gender is largely unclear. No such gender-specific differences have been observed in children suffering from IIH, especially young, prepubertal children [11–13].

Pathophysiology

The production and absorption of cerebrospinal fluid (CSF) is finely balanced. IIH was initially thought to be caused by an overproduction of CSF, a belief now largely refuted, which is why current research is focused on the absorption of CSF and venous drainage.

In IIH, patients are usually very obese, intracranial pressure is clearly correlated with BMI, and weight loss is the most effective treatment option. These facts suggest that obesity-related high intrabdominal and intrathoracic pressure increases cerebral venous pressure and reduces the absorption of CSF, ultimately causing intracranial pressure to rise. Even as plausible as this hypothesis may seem, several questions remain to be answered. It does not explain female preponderance, especially because women, unlike men, tend to accumulate fat around the hips rather than the abdomen. Moreover, the majority of obese women do not suffer from IIH, and unlike adults, children with IIH are usually not at all overweight. Obesity alone can therefore not sufficiently explain the underlying pathomechanism of IIH [13].

This has led to speculation over the last several years that various hormonal factors may be the link between obesity and IIH. Therefore, the role of hormonal processes that occur in adipose tissue receive increasing attention [14, 15]. In IIH patients, for example, the serum leptin concentration is significantly higher than in obese control subjects, pointing the discussion to central leptin resistance [16, 17]. Interestingly, leptin concentration in the affected patients is higher in women than in men, and hence this mechanism might explain why women are particularly affected by IIH. It is also known that sex hormones, especially androgen, are markedly altered in IIH patients. Because its availability is regulated by 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1), the potential role of glucocorticoids, especially cortisol, is also discussed. 11ß-HSD is especially active in adipose tissue and increased activity boosts cortisol production. Cortisol’s effect on glucocorticoid and mineralocorticoid receptors could increase the production of CSF [15]. This mechanism could not only explain the development of intracranial hypertension but also the female preponderance. However, current data does not suffice to draw specific pathophysiological conclusions.

Another hypothesis posits that one or more transverse sinus stenoses (TSS) impede venous drainage, and like the previously described mechanism, cause intracranial pressure to rise. In support of this hypothesis, TSS was identified in approximately 90% of adult IIH patients, and in cases of bilateral TSS, endovascular treatment of the stenoses may alleviate or eliminate IIH [18–20]. In contrast, hemodynamic models show that only bilateral TSS are able to block drainage enough to significantly impair CSF absorption [21]. Neither can this mechanism explain why predominantly women are affected by IIH. It is also far from clear whether TSS are primary or secondary, i.e., from external compression due to elevated intracranial pressure, because TSS in IIH are usually very prolonged and in some cases remit after pressure is relieved. If the genesis is secondary, TSS may still induce a vicious circle: high intracranial pressure could cause TSS, which could trigger or worsen a drainage block, thus impairing CSF absorption even further and thereby increasing intracranial pressure. Ultimately this would lead to a further secondary increase in TSS and could further aggravate the clinical picture. Because endovascular treatment could break this vicious circle, its efficacy cannot help to differentiate between primary and secondary TSS.

Clinical Presentation and Diagnostics

Due to increasing diagnostic options, especially imaging procedures, diagnostic criteria for IIH have been modified several times over the past decades. The current diagnostic criteria from Friedman et al. are based on a modified version of the Dandy criteria [1]. According to these criteria the presence papilledema; an unremarkable neurological examination except for cranial nerve disorders (especially parasesis of the abducens); a cMRI without structural lesions, signs of hydrocephalus or meningeal enhancement; physiological CSF composition; and opening pressure of >25 cm CSF in adults and ≥ 8 cm CSF in children (in non-sedated children of normal weight ≥ 25 cm) are required for the diagnosis of IIH [1]. A novelty in the current version of the diagnostic criteria is the possibility to diagnose IIH even in the absence of papilledema if uni- or bilateral abducens parasesis is present. If both, papiledema and abducens parasesis are absent, a definitive diagnosis is not possible, however a probable diagnosis can still be made if cMRI reveals an empty sella, a flattened posterior aspect of the optic globe, a distended periostic subarachnoid space (with or without a tortuous optic nerve) and a transverse sinus stenosis [1].

Nevertheless, leaving the diagnostic criteria aside, the clinical presentation is characterized primarily by headache, impaired vision and a number of other symptoms including cranial nerve palsies, olfactory disturbances, cognitive deficits, and tinnitus.

Headache

Up to 90% of IIH patients suffer from headache, which is the most commonly reported symptom and the main impetus for the initial medical consultation [7, 22]. IIH-associated headache is defined in the diagnostic criteria of the International Headache Society (ICHD 3 beta) [23]. A definitive diagnosis requires an elevated opening pressure of >25 cm CSF concurrent with headache that meets two of the three following criteria: Headache has developed in temporal relation to increase in intracranial pressure. In contrast to the 2004 headache criteria (ICHD-2), the current criteria no longer require headache relief after a reduction in intracranial pressure [23]. This change was absolutely essential in light of the fact that many patients can continue to suffer from chronic headache for a long time after pressure has been reduced and intracranial pressure normalized [24].

The clinical presentation of IIH-associated headache is extremely variable, which is why the clinical characteristics of headache were removed from the diagnostic criteria and mentioned only briefly in the comments [23]. The headache is typically described as a bilateral frontal or retro-orbital pressure and occurs almost
Visual disorders

IIH patients frequently suffer from visual disorders. These are primarily caused by pressure-induced papilledema, which can be identified in the overwhelming majority of patients and may be localized uni- or bilaterally [7, 26–28]. Given that IIH can occur without concomitant papilledema, it has been removed as a mandatory diagnostic criterion in the new IIH diagnostic criterion [1] and in those for IIH-associated headache (ICHD C beta) [22].

Papilledema induced by chronic intracranial pressure is usually progressive and causes numerous visual disorders. The most frequently reported visual disorders include obstructions, an enlarged blind spot, an inferior arcuate visual field defect, photopsias, and a loss of visual acuity [7, 27]. As the accompanying papilledema, which is their main underlying cause, visual disturbances are progressive and can cause irreversible deficits that may lead to complete blindness if effective pressure-reducing treatment is not initiated as soon as possible. Pathophysiologically, the chronic increase in pressure in the CSF space leads to an elevated pressure in the optic nerve tissue. This increased pressure reduces the pressure gradient between the intraocular and CSF pressure, which physiologically proceeds centripetally from the eye [29, 30]. This decreases axoplasmic transport, which in turn causes axonal swelling in the intrabulbar segment of the optic nerve [30]. The retrobulbar segment, where the nerve fibers are myelinated, is not affected. A prelaminar compression of the small, especially venous, capillaries develops secondarily to this axonal swelling. These alterations can also lead to other phenomena such as small hemorrhages in the area of the papilla. Ultimately the changes described cause atrophy of the retina and irreversible loss of optic nerve function [30]. In many cases the abducens nerve is affected, yet palsies may also occur in the oculomotor [44], trochlear [45], trigeminal [46] or facial [47] nerves, or even simultaneously in multiple cranial nerves [48]. The cranial nerve palsies usually abate after effective treatment of the elevated CSF pressure [47, 49], so the overall prognosis for these attendant symptoms is commonly good.

Abducens palsy is always accompanied by horizontal double vision and can occur uni- or bilaterally, as is the case in the other cranial nerve palsies. Abducens palsy occurs in nearly 10–20 % of adult cases of IIH [50], yet its incidence in children could be significantly higher [51]. IIH patients with an attendant abducens palsy more frequently tend to have a higher BMI and a higher CSF pressure compared to patients without cranial nerve palsy [51]. It is not exactly clear why abducens nerve palsy develops in IIH, but it is speculated that the brainstem suffers a discrete downward displacement due to the chronic increase in intracranial pressure, which puts traction on Dorello’s canal near the abducens bridge, damaging the nerves [51]. This pathomechanism could also adequately explain why abducens paresis frequently occurs bilaterally in IIH. Similar mechanisms are assumed to underlie the other IIH-associated cranial nerve alterations.

Olfactory dysfunction

Olfactory dysfunction in IIH has been known for several years [52, 53]. Approximately 80 % of IIH patients suffer from hyposmia,
although it is usually mild or moderate, which is probably why it was overlooked for so long. In a clinical study with 17 IIH patients and 17 age- and sex-matched healthy controls, Kunte et al. systematically investigated the occurrence of olfactory impairment in IIH using so-called “sniffin sticks”. This test measures odor threshold, discrimination, and identification and can be used to assess them individually and to calculate a TDI score. The study was able to demonstrate that odor discrimination and identification were significantly impaired in the majority of patients. The authors also demonstrated that the patients most affected were those diagnosed within the prior three months and who experienced significant clinical deterioration in those three months. This subgroup also evidenced a reduced odor threshold [53].

The underlying mechanisms have yet to be elucidated. Nonetheless, structural changes in the olfactory nerve are known to occur [54]. In this regard, it was shown that IIH patients, especially those in an early stage of the disease, had reduced olfactory bulb volume [54]. This is most probably the structural correlate for the frequently verifiable functional deficit [55–57]. It remains unclear whether the reduced olfactory bulb volume is simply the direct result of the increased intracranial pressure. The fact that relieving pressure through a lumbar puncture considerably improves olfactory function in a short time suggests that this may be the case [58].

**Tinnitus**

IIH patients frequently report uni- or bilateral pulsatile tinnitus [7]. The underlying cause of this alteration remains unclear. The most popular hypothesis assumes that pulsatile tinnitus could arise from one or more TSS. It is postulated that audible turbulences in the blood flow occur due to the vascular narrowing. This hypothesis is supported by the fact that invasive elimination of the stenosis using an intravascular stent frequently resolves the tinnitus. In a prospective study of 29 IIH patients with TSS and pulsatile tinnitus who were treated with a stent placed in the transverse sinus, Boddu et al. demonstrated that in all treated patients the tinnitus remitted on the day of the intervention. During the two-year follow-up phase, 10% of patients were restenosed when the tinnitus reappeared. Even though these data offer strong support for a causal relationship, other studies must be conducted to validate this pathophysiological connection especially because the number of IIH patients with stenosis who experience pulsatile tinnitus is unknown as is the number of IIH patients with tinnitus who have a TSS.

**Cognitive deficits**

Indications of cognitive deficits in IIH have been increasing for several years. The assumption was first based on case reports and small clinical studies in which individual cognitive domains were examined [59–61]. In a prospective study, Yri et al. showed that patients with IIH frequently suffer from a global cognitive dysfunction. The most severe deficits were found in processing speed and reaction time [62]. The exact mechanism that causes the identified deficits remains unclear. The deficits could conceivably be the direct result of the increased intracranial pressure, however even after intracranial pressure is normalized through adequate treatment, the cognitive deficits commonly persist at least at the three-month follow-up [62]. Therefore, some evidence points to cognitive deficits having more complex and long-lasting causes than simple mechanical compression from increasing intracranial pressure. Because patients with IIH often experience a depressed mood during their illness, which in itself can impair cognitive function, it cannot be ruled out that this kind of connection also underlies the described association. In spite of the currently available data, however, further prospective studies with longer follow-up phases are urgently needed, because the cognitive deficits significantly reduce the quality of life and are an essential burden for social participation and occupational reintegration. For these reasons, and especially because it remains unclear if the deficits are reversible, a diagnostic evaluation of IIH should also include neuropsychological testing for early detection of cognitive dysfunction.

**CSF diagnostics**

The clinical work-up for IIH requires a lumbar puncture to measure the opening CSF pressure. Not only should the opening pressure be measured, but the CSF composition should be analyzed to rule out any secondary causes. To prevent any influence on the measurements, pressure is measured with the patient in supine position and in an unsedated state. According to the current diagnostic criteria, an opening pressure of ≥25 cm CSF in adults ≥28 cm CSF in children is considered pathological [1]. CSF pressure can vary widely, even during the course of a day. If there is a justifiable suspicion of a PTC, a second lumbar puncture should be considered under certain circumstances depending on clinical symptoms [63]. Temporary continuous pressure measurement may be necessary in rare and justified cases [64, 65]. The CSF composition should be unremarkable [1].

**Magnetic resonance imaging (MRI)**

MRI has gained increasing importance in diagnosing IIH over the last several years and should be an essential component of the diagnostic evaluation. First it is required to rule out diseases that can cause a secondary increase in intracranial pressure as well as to identify IIH-specific changes. The most significant IIH-associated changes in a cerebral MRI include an empty sella, a flattened posterior aspect of the optic globe, a distended periopictic subarachnoid space with or without a tortuous optic nerve, and the presence of uni- or bilaterally localized TSS [1, 33, 66–68]. Based on the fact that TSS are verifiable in up to 90% of IIH patients and may play a causative role, an MR venography (MRV) should also be conducted in addition to a structural MRI [19]. The MRV not only allows to identify a TSS but more importantly it can also rule out sinus or cranial vein thromboses. This is particularly significant because thromboses can also occur as clinically apparent microthromboses that could still impede venous drainage and thus increase intracranial pressure and, in some circumstances, lead to further secondary TSS from the external pressure [20]. It is not yet clear whether TSS is the cause or the consequence of intracranial hypertension.

To sum up, however, it should be noted that changes identified in the MRI can substantially support the diagnosis of an IIH but due to their sensitivity and specificity current MR techniques can by no means replace lumbar puncture and measurement of the CSF opening pressure.
Treatment

The principal aims of IIH treatment are the preservation of visual acuity and the relief of headache. Treatment should always follow a multimodal approach consisting primarily of effective weight loss augmented by pharmacological treatment with carboanhydrase inhibitors. Invasive therapeutic procedures such as fenestration of the optic nerve sheaths, endovascular procedures and shunt systems should be used only in treatment-resistant cases, especially if the risk of visual loss is significant.

Weight loss

Considering the highly significant correlation between obesity and chronic intracranial hypertension, weight loss should always be the main component of treatment. Numerous studies have now shown that weight loss significantly reduces intracranial pressure, papilledema, the associated visual disturbances and headache [69]. Even small changes can have a major influence on the course of the disease. Interestingly, this is also true for patients whose weight is initially normal [8]. Successful weight loss must always be carefully monitored to ensure it is maintained, because regaining of weight is associated with an increased recurrence of IIH [70]. If weight loss cannot be maintained in the severely obese, surgical intervention through bariatric surgery should be considered, although the invasiveness of this procedure warrants restricting it to treatment-resistant cases [71].

Lumbar puncture

The lumbar puncture is the essential component of the diagnostic workup of IIH. Due to its invasiveness, however, its importance in the treatment of IIH is only secondary. It can still be considered as a bridging measure prior to an endovascular or surgical intervention in treatment-resistant situations where vision loss is imminent. The sudden drop in intracranial pressure induced by the lumbar puncture usually temporarily relieves the headache, although strictly speaking this observation has not yet been proven in any prospective clinical study. The same is true for the effect of the acute drop in pressure on other IIH-associated symptoms. Interestingly, the lessening of headache intensity in some IIH patients lasts for several weeks, although the amount of fluid drained is replaced after a few hours [72]. Even a puncture-induced leak persisting several days cannot sufficiently explain this observation. It is feasible, however, that relieving the pressure reestablishes a stable equilibrium between CSF production and absorption, thus reducing secondary pressure-induced TSS and thereby improving venous drainage and CSF absorption [73–76]. Further studies are needed to confirm this hypothesis.

Pharmaceutical treatment

Carboanhydrase inhibitors form the first-line pharmaceutical treatment of IIH. Carboanhydrase is localized in the choroid plexus and regulates the production of hydrogen carbonate (HCO$_3^-$) and hence CSF secretion [77]. Inhibiting this enzyme reduces CSF production [78] and therefore reduces CSF pressure [79].

Acetazolamide is the most frequently used carboanhydrase inhibitor in the treatment of IIH, and the typical dose range is between 500–2 000 mg. Although administered for many years to treat IIH, until recently the use acetazolamide had been based on the results of open or uncontrolled studies without a placebo group [80, 81]. The first randomized placebo-controlled study on the efficacy of acetazolamide in treating IIH was conducted just a few years ago. The study showed that acetazolamide, at the study dose of up to 4 g daily, improved papilledema, visual deficits, and headache [82]. In spite of the relatively frequent gastrointestinal side effects, the treatment significantly improved quality of life [83]. This clinical improvement in all the aspects cited continued throughout a follow-up period of 12 months [84]. Acetazolamide brought about significant weight loss in the study, which probably contributed substantially to its efficacy [82, 85].

In cases where acetazolamide is not effective, tolerated, or contraindicated, topiramate can be given as an alternative at a dose between 50–200 mg. To date, however, there have been no randomized, placebo-controlled studies to verify its efficacy. Only a few open studies without a placebo group suggest its efficacy in IIH [80, 86]. Paresthesias, mood swings, and cognitive deficits are among the most frequent side effects [87]. The essential mode of action is thought to be the inhibition of the carboanhydrase. Topiramate frequently also leads to significant weight loss, however, thus likely substantially contributing to its efficacy.

Furosemide is yet another pharmaceutical option. Furosemide also inhibits carboanhydrase, thereby reducing CSF production and hence CSF pressure [88]. The dosage range for the treatment of IIH is usually between 30 and 80 mg a day. There have been no randomized, placebo-controlled studies on its efficacy in the treatment of IIH to date.

Besides the carboanhydrase inhibitors described, octreotide is showing promise for use in IIH. This drug is a long-acting, synthetic somatostatin analog that also inhibits the effect of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Existing data suggest that octreotide could considerably improve papilledema and the associated visual deficits as well as the headache [89–92]. Its efficacy thereby extends far beyond its known analgesic effect [93]. Its precise mode of action in IIH is unknown. The idea to use octreotide originated from the observation that treatment with GH or IGF-1 could trigger a secondary PTC [90, 94]. However, the patients treated in the three cited studies suffered from IIH, i.e., there were no pathological hormonal changes present. All studies were open studies or case reports, however, so further studies to test its efficacy are essential.

Endovascular treatment

An endovascular stent can be an effective treatment option in the case of one or more verified stenoses in the transverse sinus [18, 20]. The specific mode of action remains unclear, but it is assumed that eliminating the TSS improves venous drainage, which in turn increases CSF absorption, ultimately reducing CSF pressure [95, 96]. In spite of the relatively good data on its efficacy, endovascular treatment should be considered only in treatment-resistant cases. For one thing, the long-term data on efficacy and safety is limited. Furthermore, complications such as stent displacement, in-stent thrombosis, or sinus perforation with consecutive subdural hematoma are not uncommon [97].
Fenestration of the optical nerve sheaths

This invasive procedure consists of an incision in the meninges surrounding the optical nerve. The mode of action has not yet been elucidated. It is assumed that the incision reduces the CSF pressure around the optic nerve, but it is not clear why this effect persists even though the meningeal lesion heals after a short time, thereby eliminating the CSF leak. Numerous studies have already proven the efficacy of fenestration in reducing papilledema and its associated visual deficits, however data on its long-term efficacy and safety are insufficient [98, 99]. This intervention should therefore be considered only in particular treatment-resistant cases where the risk of irreversible vision loss is high [6].

CSF diversion procedures

A shunt system aims to reduce pressure by circumventing the physiological CSF drainage pathway. Either a ventriculoperitoneal or a lumboperitoneal shunt can be used, whereby the former is preferable because it is associated with a lesser risk of side effects and necessary shunt revisions [100]. Nonetheless, potentially dangerous side effects such as shunt infection or dysfunction can occur with the procedure. Furthermore, data on long-term efficacy and safety are sparse [101]. This data does suggest that in most cases placement of a shunt system positively affects the visual deficits but not the headache. Furthermore, for a variety of reasons more than half of the patients require a shunt revision [101, 102]. Against this backdrop, this intervention should be considered only in treatment-resistant patients with a significant risk of irreversible vision loss.

Conflict of interest

J. Hoffmann received fees for consulting, and/or other advisory board activities from Allergan, Autonomic Technologies Inc. (ATI), Chordate Medical and Novartis. He also received fees for lecturing activities from Allergan, Novartis and Teva. There is no conflict of interest with respect to the content of this manuscript. In the last two years, A. May has received and/or continues to receive funding from the German Research Association (DFG), the Federal Ministry of Education and Research (BMBF), and the European Union. He also has an unrestricted grant from Chordate Medical and Novartis. He also received fees for lecturing board activities from Allergan, Autonomic Technologies Inc. (ATI), ElectroCore, TEVA and Desitin. There is no conflict of interest with respect to the content of this manuscript.

References


